Cardiac Dimensions touts 10-year survival data from single-center mitral device study
A single-center extension of the completed REDUCE FMR trial reports 66% ten-year survival with no control comparison, as the sponsor's real evidence for U.S. approval now rests on the ongoing sham-controlled EMPOWER trial.
Executive Summary
- Cardiac Dimensions released ten-year survival figures from a single-center extension of a trial that completed its primary analysis years earlier, reframing older data as new long-term evidence.
- The figures come without a concurrent control group or formal statistical testing, so they describe an outcome in a treated population rather than demonstrate a treatment effect.
- The device's path to U.S. approval runs through a separate, ongoing randomized sham-controlled trial, which is the disclosure that will actually determine whether the therapy's benefit holds under blinded comparison.
- No competing device shares indirect mitral annuloplasty's mechanism in functional mitral regurgitation, leaving this program without a direct comparator even as several structurally different mitral and heart-failure devices advance in parallel.
The disclosure
Cardiac Dimensions said on July 8, 2026, that a single-center extension of the REDUCE FMR trial (NCT02325830) found 10-year cardiovascular survival of 66% and median survival of 5.6 years among patients treated with its Carillon Mitral Contour System for functional mitral regurgitation. The company framed the finding as evidence of long-term durability, calling it, in its release, part of "the most comprehensive evidence base ever assembled for transcatheter indirect mitral annuloplasty". The underlying trial enrolled 163 patients, reached its primary completion date on July 1, 2018, and has been listed as Completed on the registry since then. NCT02325830+1Carillon Mitral Contour System® for Reducing Functional Mitral RegurgitationNCT02325830Cardiac Dimensions® Announces Three Major Publications Demonstrating Long-Term Durability, Real-World Performance, and Broad Patient Benefit of the Carillon Mitral Contour System®Jul 8, 2026
What REDUCE FMR was designed to test
The REDUCE FMR trial's registered primary endpoint measured change in regurgitant volume against a control group receiving optimized medical therapy, assessed at 12 months in a 120-patient intent-to-treat population, not survival at ten years. Its posted results also tracked heart failure hospitalization rate, six-minute walk distance and left ventricular volumes as secondary measures, alongside serious adverse events including heart failure exacerbation, arrhythmia and endocarditis across treatment and control arms. The ten-year survival figures the company published this month sit outside that original endpoint structure: they come from a single-center subset, carry no concurrent control arm, and were reported descriptively without formal hypothesis testing. That distinction matters because a survival rate in a treated cohort, without a comparator, cannot establish whether the device changed the outcome or whether the cohort's own risk profile drove it. NCT02325830+1Carillon Mitral Contour System® for Reducing Functional Mitral RegurgitationNCT02325830Cardiac Dimensions® Announces Three Major Publications Demonstrating Long-Term Durability, Real-World Performance, and Broad Patient Benefit of the Carillon Mitral Contour System®Jul 8, 2026
Sponsor framing versus registry status
The release grouped the ten-year survival data alongside two other publications, a 228-patient multi-center CINCH FMR registry showing MR grade improvement through five years and a 204-patient single-center analysis spanning both reduced and preserved ejection fraction, and positioned all three as building toward U.S. regulatory submissions. The underlying event record flags sponsor spin and post-hoc emphasis in how the survival result was presented. None of the three publications is a randomized, controlled primary-endpoint readout; REDUCE FMR itself has carried a Completed status with no protocol amendments since its 2018 primary completion and 2024 results posting. Cardiac+1Cardiac Dimensions® Announces Three Major Publications Demonstrating Long-Term Durability, Real-World Performance, and Broad Patient Benefit of the Carillon Mitral Contour System®Jul 8, 2026Carillon Mitral Contour System® for Reducing Functional Mitral RegurgitationNCT02325830
Where the real evidence now sits
Cardiac Dimensions said it is advancing toward U.S. approval through the EMPOWER trial, a pivotal, randomized, sham-controlled study designed to enroll up to 300 patients. That trial, not the ten-year REDUCE FMR extension, will generate the blinded comparison against a sham procedure that a device seeking U.S. approval in this indication needs. No competitor trial shares indirect mitral annuloplasty's specific mechanism against functional mitral regurgitation in the trials surfaced for this indication; the nearest comparators, including Medtronic's Intrepid TMVR system and Edwards' SAPIEN-based mitral programs, use different device mechanisms entirely. Cardiac Dimensions' only other trial of the Carillon system, a small atrial functional MR study enrolling four patients, was terminated in September 2021. CardiacCardiac Dimensions® Announces Three Major Publications Demonstrating Long-Term Durability, Real-World Performance, and Broad Patient Benefit of the Carillon Mitral Contour System®Jul 8, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.